期刊文献+

新型镇痛多肽Eb1.6的含量及有关物质检测 被引量:2

Determination of content of novel analgesic conopeptide Eb1.6 and its related substances
原文传递
导出
摘要 目的:建立一种适用于新型alpha芋螺镇痛多肽Eb1.6含量及有关物质的分析方法,以及其水分和乙酸的含量测定方法。方法:采用高效液相色谱法测定Eb1.6原料药中Eb1.6的含量。使用Zorbax XDB-C18色谱柱(150 mm×4.6 mm,5μm),流动相A为含0.1%三氟乙酸(TFA)的水,流动相B为含0.1%TFA的乙腈,梯度洗脱,流速1 m L·min-1,检测波长214 nm,柱温25℃;采用卡尔菲休库仑滴定法及高效液相色谱法测定样品中水分及乙酸含量。结果:3批Eb1.6原料药中Eb1.6含量范围在(98.85±0.63)%^(99.04±0.33)%之间(按无水物计算),总有关物质含量在0.45%~0.84%之间,样品中水分含量在(1.23±0.32)%^(2.23±0.23)%之间,乙酸含量在(11.16±0.08)%^(12.66±0.03)%之间。结论:该方法快速简便,结果准确可靠,可用于Eb1.6的质量分析。 Objective: To established a method to determine the content of novel analgesic conopeptide Ebl. 6 and its related substances as well as the content of moisture and acetic acid. Methods: Ebl. 6 was detected with Zorbax Eclipse XDB - C18 column( 150 mm×4.6 mm,5 μm) at the detection wavelength of 214 nm with the flow rate of 1.0 mL · min^- 1. The mobile phase A was 0. 1% TFA, the mobile phase B was 0. 1% CH3 CN, the gradient elution was adopted. The column temperature was 25 ℃C. The water content of Ebl. 6 was determined by Karl Fischer coulo- metric titration method, and the content of acetic acid was determined by HPLC method. Results: The content of Ebl. 6 in three batches of crude drugs was in the range of(98.85 ± 0. 63) % - (99.04 ± 0. 33 ) % ( calculated by anhydride), while the content of total related substances was from 0.45 % to 0. 84%, the water content was ( 1.23 ±0.32) % - (2.23 ± 0. 23 ) % and the content of acetic acid was( 11.16 ± 0. 08) % - ( 12.66± 0.03 ) %. Conclusion: The method is reliable, accurate and specific. It can be used for quality analysis of Ebl. 6.
出处 《药物分析杂志》 CAS CSCD 北大核心 2014年第12期2166-2170,共5页 Chinese Journal of Pharmaceutical Analysis
基金 海洋863项目(2011AA09070108)
关键词 芋螺多肽 镇痛多肽 Eb1.6 有关物质 水分 乙酸 高效液相色谱 卡尔菲休库仑滴定 conotoxin peptide analgesic peptide Ebl. 6 related substances water content acetic acid HPLC Karl Fischer coulometric titration method
  • 相关文献

参考文献10

  • 1Lee MS.Recent progress in the discovery and development of N-type calcium channel modulators for the treatment of pain[J].Prog Med Chem,2014,53:147.
  • 2Pope JE,Deer TR.Ziconotide: a clinical update and pharmacologic review[J].Expert Opin Pharmacol Ther,2013,14(7):957.
  • 3Brady RM,Baell JB,Norton RS.Strategies for the development of conotoxins as new therapeutic leads[J].Mar Drugs,2013,11(7):2293.
  • 4Adams DJ,Berecki G.Mechanisms of conotoxin inhibition of N-type(Ca(v)2.2)calcium channels[J].Biochim Biophys Acta,2013,1828(7):1619.
  • 5Adams DJ,Callaghan B,Berecki G.Analgesic conotoxins: block and G protein-coupled receptor modulation of N-type(CaV2.2)calcium channels[J].Br J Pharmacol,2012,166(2):486.
  • 6LIU Zhu-guo(刘珠果),DAI Qiu-yun(戴秋云),SUN Ting(孙婷),et al.Applications of a-conotoxins(α型芋螺多肽及其应用): China(中国),201010121879.7[P].2011-05-25.
  • 7徐艳,余硕,姬泓巍,董铭心,王孝花,吴巧玲,戴秋云.芋螺多肽Eb1.6的制备工艺研究[J].军事医学,2013,37(4):274-278. 被引量:1
  • 8余硕,郭会芹,付超,徐艳,戴秋云.抗HIV融合多肽CP32M的质量分析[J].军事医学,2012,36(11):839-842. 被引量:1
  • 9郭会芹,王于,付超,姬泓巍,戴秋云.新型抗凝血多肽Hirulog-S的质量分析[J].药物分析杂志,2011,31(10):1930-1933. 被引量:3
  • 10ChP 2010.Vol Ⅱ(中国药典2010年版.二部)[S].2010:Appendix(附录)VD.

二级参考文献28

  • 1魏娟娟,戴秋云.α-芋螺毒素构效关系的研究进展[J].军事医学科学院院刊,2006,30(4):389-393. 被引量:11
  • 2DAI Qiu-yun (戴秋云),HUANG Yuan-yuan (黄园园),DONG Ming-xin (董铭心),et al.Anticoagulated peptides and their usage(一类抗凝血多肽及其用途),China Invention Patent Number:ZL200710120685;International PCT Patent Application Number:PCT/CN2008/001881.
  • 3Pan GX,Wang XM,Huang YH,et al.Development and validation of a LC-MS/MS method for determination of bivalirudin in human plasma:Application to a clinical pharmacokinetic study.J Pharm Biomed Anal,2010,52:105.
  • 4Deeks ED,Curran MP.Bivalirudin:in patients with acute coronary syndromes:planned for urgent or early intervention.Drugs,2008,68(16):2345.
  • 5ChP(中国药典).2005.Vol Ⅲ(三部):186.
  • 6Teixeira C, Gomes JR, Gomes P, et al. Viral surface glycopro- teins, gpl20 and glM1, as potential drug targets against HIV-1.Brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug [ J]. Eur J Med Chem, 2011,46(4) :979 -992.
  • 7Naider F, Anglister J. Peptides in the treatment of AIDS [J]. Curt Opin Struct Biol,2009,19(4) :473 -482.
  • 8Mattews T, Salgo M, Greenherg M, et al . Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CIM lymphocytes [J]. Nat Rev, 2004, 3(3) : 215 -225.
  • 9Baldwin CE, Sanders RW, Deng Y, et al. Emergence of a drug- dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor [ J]. J Virol, 2004,78 (22) :12428 - 12437.
  • 10He YX, Chen JW, Lu H, et al. Potent HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strains [ J ]. Proc Natl Acad Sci USA, 2008,105 (42) : 16332 - 16337.

共引文献6

同被引文献14

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部